SBIR-STTR Award

Development of a Breath Analyzer for Asthma Screening
Award last edited on: 11/29/05

Sponsored Program
SBIR
Awarding Agency
NIH : NHLBI
Total Award Amount
$853,321
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Khosrow Namjou

Company Information

Ekips Technologies Inc (AKA: Ekips Tech)

710 Asp Avenue Suite 500
Norman, OK 73069
   (405) 307-8803
   info@ekipstech.com
   www.ekipstech.com
Location: Single
Congr. District: 04
County: Cleveland

Phase I

Contract Number: 1R43HL070344-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2002
Phase I Amount
$100,000
Development of a laser-based breath analyzer is proposed for measuring nitric oxide (NO) in exhaled breath of asthmatic patients. Preliminary results using a prototype breath tester demonstrated the feasibility of the proposed technique for measuring trace NO in exhaled breath. A correlation between above-normal levels of NO with asthma condition has been establishes. Te objective of this Phase I project is to build a prototype instrument suitable for use in a clinical setting. Success of Phase I will be measured by generation of clinically useful data for treatment and management of asthma. Asthma is characterized by chronic airway inflammation and increased synthesis of NO in expired air. In the proposed project, Ekips Technologies Inc. will exploit its extensive background in mid-IR laser technology, trace gas detection, and computer interfacing to develop a very sensitive apparatus for non-invasive monitoring of exhaled NO. The long-term goal of the project is commercialization of the proposed technique as a clinical-based sensor for quick and large-scale diagnosing asthma in children and adults. In collaboration with Allergy Clinic of Tulsa, at least 100 breath tests will be performed during Phase I.

Thesaurus Terms:
asthma, biomedical equipment development, breath test, diagnosis design /evaluation, patient monitoring device, respiratory disorder diagnosis, respiratory function, respiratory gas analyzer carbon dioxide, laser, nitric oxide, noninvasive diagnosis clinical research, human subject

Phase II

Contract Number: 2R44HL070344-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2004
(last award dollars: 2005)
Phase II Amount
$753,321

An innovative instrument for measuring exhaled compounds was demonstrated in Phase I of this project. The novel breath monitor (Breathmeter TM) consists of a tunable mid-IR diode laser, a long optical resonator, and electronics modules for detecting select molecular species in exhaled breath. This system can solve the challenging problem of finding a cost effective, highly sensitive, real-time, monitoring scheme for identifying and quantifying exhaled biomarkers related to airway inflammation and asthma. In Phase I research the technical feasibility of the concept was proved by measurement of exhaled nitric oxide (eNO) and carbon dioxide (eCO2) in a clinical setting. Using the first prototype system, 368 adult and pediatric patients were tested in pulmonary clinics by respiratory therapists using the device under the supervision of a pulmonologist or an allergy immunology specialist. The data collected indicate a correlation between above-normal levels of eNO and asthma. In addition, early longitudinal data indicate that the instrument will be useful for anti-inflammatory treatment monitoring. Early testing also indicates minority and socio-economic asthmatic population differences consistent with previous studies. The long-term goal of the project is commercialization of the proposed technique for quick and large-scale identification of airway inflammation (a precursor condition for asthma) and monitoring of anti-inflammatory treatments in children and adults. NIH SBIR Phase II R&D efforts will concentrate on additional clinical research to 1) sample levels of exhaled nitric oxide in a large population and 2) conduct clinical research correlating eNO with specific respiratory diseases. Thus, the major objectives for Phase II will be: conducting clinical research necessary for demonstrating adequate clinical utility in order to begin clinical trials for FDA approval. To accomplish this Phase II research, additional Breathmeter prototypes will be constructed and medical technicians and clinicians will be recruited to perform work with these instruments. The Ekips Breathmeter has the opportunity to obtain a significant share of the pulmonary function testing market within two years after receiving FDA approval.

Thesaurus Terms:
asthma, biomedical equipment development, breath test, diagnosis design /evaluation, patient monitoring device, respiratory disorder diagnosis, respiratory function, respiratory gas analyzer carbon dioxide, laser, longitudinal human study, nitric oxide, noninvasive diagnosis clinical research, human subject